非小细胞肺癌的肿瘤干细胞与非肿瘤干细胞中表皮生长因子受体(EGFR) 基因异质性的相关研究.docVIP

非小细胞肺癌的肿瘤干细胞与非肿瘤干细胞中表皮生长因子受体（EGFR）基因异质性的相关研究 蒋 娟1，易亭伍1，张 瑜1，兰 洁1，卢 铀1，2 （610041成都，四川大学华西医院：肿瘤中心胸部肿瘤科1，生物治疗国家重点实验室2） [摘要] 目的研究非小细胞肺癌（non-small-cell lung cancer, NSCLC）的肿瘤干细胞和非肿瘤干细胞中表皮生长因子受体（EGFR）基因状态，EGFR-TKIs的。方法收集2010年6月2011年8月四川省肿瘤医院及四川大学华西医院胸外科NSCLC新鲜手术标本35例，流式细胞术分选出CD133+细胞和CD133-细胞，采用扩增阻滞突变系统（ARMS）分别检测EGFR基因突变，观察其有无差异。结果35例NSCLC样本中均检测到CD133+细胞的存在。11例患者标本CD133+/-细胞存在EGFR基因异质性，占31.4%（11/35）。24例患者标本CD133+-细胞EGFR基因状态相同（18例患者中CD133+和CD133-细胞EGFR均为野生型，6例患者中CD133+和CD133-细胞EGFR为相同的敏感性突变）结论在NSCLCCD133+细胞和CD133-细胞存在EGFR基因异质性。R730.54；R734.2 [文献标志码] A The Epidermal Growth Factor Receptor（EGFR） Cancer Stem Cells and Non-Cancer Stem Cells in Non-Small-Cell Lung Cancer (NSCLC) Jiang Juan,Yi Tingwu,Zhang Yu,Lan Jie,Lu You（Department of Thoracic Oncology，Cancer Center，West China Hospital，Sichuan University，Chengdu 610041，China） [Abstract] Objective To investigate the epidermal growth factor receptor (EGFR) genetic status in cancer stem cells (CSCs) and non-cancer stem cells of non-small-cell lung cancer (NSCLC) for the purpose to guide the EGFR-TKIs treatment. Methods Thirty-five NSCLC surgical fresh specimens in total were collected from West China Hospital and The Second Peoples Hospital of Sichuan from June 2010 to August 2011. CD133-positive cells and CD133-negative cells were sorted by flow cytometry after CD133 staining. Amplification refractory mutation system (ARMS) method was employed to detect the presence of EGFR mutations in the two types of cells. The correlation of the EGFR mutations in different cells was analyzed. Results CD133-positive cells were detected in all of the collected specimens. There were 11 specimens out of 35 which had EGFR gene heterogeneity in both CD133-positive cells and CD133-negative cells (11/35, 31.4%). The remaining 24 specimens had the same EGFR gene status in both CD133-positive cells and CD133-negative cells (18 cases exhibited EGFR wild type in both CD133-positive and –negative cells, and 6 cases